ENDOLOGIX, INC. April 29, 2016
IRVINE, Calif., April 29, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, are scheduled to participate at two investor conferences in May. The first conference is the Deutsche Bank 41 Annual Health Care Conference in Boston, Massachusetts.
| Event: | Deutsche Bank 41 Annual Health Care Conference |
| Date: | Thursday May 5, 2016 |
| Time: | 11:20 am ET |
| Participant: | Vaseem Mahboob, Chief Financial Officer |
The second conference is the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, Nevada.
| Event: | Bank of America Merrill Lynch 2016 Health Care Conference |
| Date: | Tuesday May 10, 2016 |
| Time: | 6:40 pm ET / 3:40 pm PT |
| Participants: | John McDermott, Chief Executive Officer |
| Vaseem Mahboob, Chief Financial Officer |
An audio webcast of the Company's presentations at these conferences will be available by visiting the investor relations section of Endologix's website at www.endologix.com. A replay of the presentation will be available for 30 days.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.
COMPANY CONTACT:
Endologix, Inc.John McDermott, CEO
Vaseem Mahboob, CFO
(949) 595-7200
www.endologix.com
INVESTOR CONTACTS:
The Ruth GroupNick Laudico (646) 536-7030
Zack Kubow (646) 536-7020
Source: Endologix
News Provided by Acquire Media
Close window | Back to top
Endologix Inc. published this content on 29 April 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 09 May 2016 20:19:11 UTC.
Original documenthttp://investor.endologix.com/releasedetail.cfm?ReleaseID=968218
Public permalinkhttp://www.publicnow.com/view/77A539D074CDDF0E545555D851FA2F42424C0C7F
